Introduction

Indication[1]

Foslevodopa/foscarbidopa solution is indicated for the treatment of **motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease (PD) who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia** despite optimized treatment with available combinations of PD medicinal products.

Foslevodopa/foscarbidopa should only be prescribed by neurologists who are experienced in the treatment of patients with PD.

Administration[1]

Foslevodopa/foscarbidopa is administered via **24-hour continuous SC infusion**, in the abdomen, avoiding a 5-cm radius around the navel and not be infused into areas where the site is tender, bruised, red or hard to the touch.

The infusion set (cannula) can remain in place for up to **3 days**.

Preparation and Equipment[1]

Employ **aseptic technique** for preparation and administration. Use the **VYAFUSER™ Pump** and only sterile, single-use components (syringe, infusion set, vial adapter).

Click to open the product monograph


Product Monograph
Including Patient Medication Information
PrVYALEV®

foslevodopa/foscarbidopa Solution
For subcutaneous infusion use
240 mg/mL foslevodopa and 12 mg/mL foscarbidopa
Antiparkinson Agent
ATC Code: N04BA0

AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Qc H4S 1Z1

Date of Authorization:
2026-04-14

Control Number: 297629

VYALEV (foslevodopa/foscarbidopa solution) Page 1 of 53

Note: This tool does not include all the information from the product monograph. Please refer to the complete document for more details about foslevodopa/foscarbidopa. 1. AbbVie Corporation. PrVYALEV™ Product Monograph. April 14, 2026/p5/Indications / p11/ Administration. www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/VYALEV_PM_EN.pdf
SC, subcutaneous.